1887

Journal of General Virology header logo

Volume 80, Issue 11

Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis Free

Abstract

Human papillomavirus (HPV) exists as more than 100 genotypes. It is not well-established whether the different HPV types interfere with infection or pathogenesis by each other. Possible interactions in cervical carcinogenesis between infection with the most common HPV types (6, 11, 16, 18 and 33) were studied in a seroepidemiological case- control study of 218 women with primary untreated cervical cancer and 219 healthy age-matched control women. As previously shown, HPV-16 seropositivity was associated with cervical cancer risk [odds ratio (OR), 2·39], but HPV-16 was not associated with cervical cancer risk among HPV-6 seropositive women (OR, 1·0). The relative excess risk due to interaction between HPV-6 and -16 was −2·35 (95% confidence interval, −0·04 to −4·65), indicating significant antagonism. The results suggest that infection with HPV-6 may interfere with HPV-16-associated cervical carcinogenesis.

  • Received:
  • Accepted:
  • Published Online:
© Microbiology Society
Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-80-11-2931
1999-11-01
2024-04-16
Loading full text...

Full text loading...

/deliver/fulltext/jgv/80/11/0802931a.html?itemId=/content/journal/jgv/10.1099/0022-1317-80-11-2931&mimeType=html&fmt=ahah

References

  1. af Geijersstam V., Kibur M., Wang Z., Koskela P., Pukkala E., Schiller J., Lehtinen M., Dillner J. 1998; Stability over time of serum antibody levels to human papillomavirus type 16. Journal of Infectious Diseases 177:1710–1714
     [Google Scholar]
  2. Björge T., Dillner J., Anttila T., Engeland A., Hakulinen T., Jellum E., Lehtinen M., Luostarinen T., Paavonen J., Pukkala E., Sapp M., Schiller J., Youngman L., Thoresen S. 1997; Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. British Medical Journal 315:646–649
     [Google Scholar]
  3. Breitburd F., Kirnbauer R., Hubbert N. L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., Schiller J. T., Lowy D. R. 1995; Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. Journal of Virology 69:3959–3963
     [Google Scholar]
  4. Carter J. J., Koutsky L. A., Wipf G. C., Christiansen N. D., Lee S. K., Kuypers J., Kiviat N., Galloway D. A. 1996; The natural history of HPV 16 capsid antibodies among a cohort of university women. Journal of Infectious Diseases 174:927–936
     [Google Scholar]
  5. Christensen N. D., Reed C. A., Cladel N. M., Hall K., Leiserowitz G. S. 1996; Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 224:477–486
     [Google Scholar]
  6. Chuang T. Y., Perry H. O., Kurland L. T., Ilstrup D. M. 1984; Condyloma acuminatum in Rochester, Minn, 1950–1978. II. Anaplasias and unfavorable outcomes. Archives of Dermatology 120:476–483
     [Google Scholar]
  7. Dillner J., Lenner P., Lehtinen M., Eklund C., Heino P., Wiklund F., Hallmans G., Stendahl U. 1994; A population-based seroepidemiological study of cervical cancer. Cancer Research 54:134–141
     [Google Scholar]
  8. Dillner J., Wiklund F., Lenner P., Eklund C., Fredriksson-Shanazarian V., Schiller J. T., Hibma M., Hallmans G., Stendahl U. 1995; Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with incident cervical cancer. International Journal of Cancer 60:377–382
     [Google Scholar]
  9. Dillner J., Kallings I., Brihmer C., Sikstrom B., Koskela P., Lehtinen M., Schiller J. T., Sapp M., Mardh P. A. 1996; Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour. Journal of Infectious Diseases 173:1394–1398
     [Google Scholar]
  10. Dillner J., Lehtinen M., Björge T., Luostarinen T., Youngman L., Jellum E., Koskela P., Gislefoss R. E., Hallmans G., Paavonen J., Sapp M., Schiller J. T., Hakulinen T., Thoresen S., Hakama M. 1997; Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. Journal of the National Cancer Institute 89:1293–1299
     [Google Scholar]
  11. Donato F., Boffetta P., Puoti M. 1998; A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. International Journal of Cancer 75:347–354
     [Google Scholar]
  12. Evander M., Edlund K., Gustafsson A., Jonsson M., Karlsson R., Rylander E., Wadell G. 1995; Human papillomavirus infection is transient in young women: a population-based cohort study. Journal of Infectious Diseases 171:1026–1030
     [Google Scholar]
  13. Evans B. A., Bond R. A., MacRae K. D. 1992; A colposcopic case- control study of cervical squamous intraepithelial lesions in women with anogenital warts. Genitourinary Medicine 68:300–304
     [Google Scholar]
  14. Greenland S. 1993; Additive risk versus additive relative risk models. Epidemiology 4:32–36
     [Google Scholar]
  15. Heino P., Skyldberg B., Lehtinen M., Rantala I., Hagmar B., Kreider J. W., Kirnbauer R., Dillner J. 1995; Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes. Journal of General Virology 76:1141–1153
     [Google Scholar]
  16. Hildesheim A., Mann V., Brinton L. A., Szklo M., Reeves W. C., Rawls W. E. 1991; Herpes simplex virus type 2: a possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancer. International Journal of Cancer 49:335–340
     [Google Scholar]
  17. Hildesheim A., Gravitt P., Schiffman M. H., Kurman R. J., Barnes W., Jones S., Tchabo J. G., Brinton L. A., Copeland C., Epp J. 1993; Determinants of genital human papillomavirus infection in low-income women in Washington, D. C. Sexually Transmitted Diseases 20:279–285
     [Google Scholar]
  18. Hosmer D. W., Lemeshow S. 1992; Confidence interval estimation of interaction. Epidemiology 3:452–456
     [Google Scholar]
  19. Kirnbauer R., Hubbert N. L., Wheeler C. M., Becker T. M., Lowy D. R., Schiller J. T. 1994; A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. Journal of the National Cancer Institute 86:494–499
     [Google Scholar]
  20. Kirnbauer R., Chandrachud L. M., O’Neil B. W., Wagner E. R., Grindlay G. J., Armstrong A., McGarvie G. M., Schiller J. T., Lowy D. R., Campo M. S. 1996; Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219:37–44
     [Google Scholar]
  21. Kjaer S. K., de Villiers E. M., Caglayan H., Svare E., Haugaard B. J., Engholm G., Christensen R. B., Moller K. A., Poll P., Jensen H. 1993; Human papillomavirus, herpes simplex virus and other potential risk factors for cervical cancer in a high-risk area (Greenland) and a low-risk area (Denmark) – a second look.. British Journal of Cancer 67:830–837
     [Google Scholar]
  22. Lehtinen M., Dillner J., Knekt P., Luostarinen T., Aromaa A., Kirnbauer R., Koskela P., Paavonen J., Peto R., Schiller J. T., Hakama M. 1996; Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. British Medical Journal 312:537–539
     [Google Scholar]
  23. Lipsitch M. 1997; Vaccination against colonising bacteria with multiple serotypes. Proceedings of the National Academy of Sciences USA: 94:6571–6576
     [Google Scholar]
  24. Luostarinen T., af Geijersstam V., Björge T., Eklund C., Hakama M., Hakulinen T., Jellum E., Koskela P., Paavonen J., Pikkala E., Schiller J. T., Thoresen S., Youngman L. D., Dillner J., Lehtinen M. 1999; No excess risk of cervical carcinoma among women seropositive for both HPV 16 and HPV 6/11. International Journal of Cancer 80:818–822
     [Google Scholar]
  25. Schiller J. T., Thoresen S., Youngman L. D., Lehtinen M. 1999; No excess risk of cervical carcinoma among women seropositive for both HPV 16 and HPV 6/11. International Journal of Cancer 80:818–822
     [Google Scholar]
  26. May R. M., Nowak M. A. 1995; Coinfection and the evolution of parasite virulence. Proceedings of the Royal Society of London Series B 261:209–215
     [Google Scholar]
  27. Olsen A. O., Dillner J., Gjoen K., Magnus P. 1997; Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Genitourinary Medicine 73:131–135
     [Google Scholar]
  28. Rothman K. J., Greenland S. 1998 Modern Epidemiology Philadelphia: Lippincott–Raven;
  29. Shah K. V., Viscidi R. P., Ahlberg A. J., Helzlsouer K. J., Comstock G. W. 1997; Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiology, Biomarkers & Prevention 6:233–237
     [Google Scholar]
  30. Sigurgeirsson B., Lindelof B., Eklund G. 1991; Condylomata acuminata and risk of cancer: an epidemiological study. British Medical Journal 303:341–344
     [Google Scholar]
  31. Strickler D. H., Schiffman M. H., Eklund C., Glass A. G., Scott D. R., Sherman M. E., Wacholder S., Kurman R. J., Manos M. M., Schiller J. T., Dillner J. 1997; Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions. Cancer Epidemiology, Biomarkers & Prevention 6:183–188
     [Google Scholar]
  32. Suzich J. A., Ghim S. J., Palmer-Hill F. J., White W. I., Tamura J. K., Bell J. A., Newsome J. A., Jenson A. B., Schlegel R. 1995; Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proceedings of the National Academy of Sciences USA: 92:11553–11557
     [Google Scholar]
  33. Vonka V., Hamsikova E., Kanka J., Ludvikova V., Sapp M., Smahel M. 1999; Prospective study on cervical neoplasia IV. Presence of HPV antibodies. International Journal of Cancer 80:365–368
     [Google Scholar]
  34. Wang Z., Konya J., Åvall-Lundqvist E., Sapp M., Dillner J., Dillner L. 1997; Human papillomavirus antibody responses among patients with incident cervical carcinoma. Journal of Medical Virology 52:436–440
     [Google Scholar]
  35. Wikström A., van Doornum G. J. J., Kirnbauer R., Quint W. G. V., Dillner J. 1995; A prospective study on the development of antibodies against human papillomavirus type 6 among patients with condyloma acuminata or new asymptomatic infection. Journal of Medical Virology 46:368–374
     [Google Scholar]
  36. zur Hausen H. 1996; Papillomavirus infections – a major cause of human cancers. Biochimica et Biophysica Acta 1288:F55–78
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-80-11-2931
Loading
Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis
J. Gen. Virol. 80, 2931 (1999); https://doi.org/10.1099/0022-1317-80-11-2931
/content/journal/jgv/10.1099/0022-1317-80-11-2931
/content/journal/jgv/10.1099/0022-1317-80-11-2931
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error